Phentermine/topiramate
| Combination of | |
|---|---|
| Phentermine | Appetite suppressant/stimulant of the amphetamine and phenethylamine class |
| Topiramate | Anticonvulsant (extended release formulation is used) |
| Clinical data | |
| Pronunciation | /kjuːsɪˈmiːə/ kew-sim-EE-ə |
| Trade names | Qsymia |
| AHFS/Drugs.com | Professional Drug Facts |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| (verify) | |
Phentermine/topiramate, sold under the brand name Qsymia, is a combination drug of phentermine and topiramate used to treat obesity.[1] It is used together with dietary changes and exercise.[2] If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped.[2] The weight loss is modest.[2] Effects on heart related health problems or death is unclear.[2]
Common side effects include tingling, dizziness, trouble sleeping, and constipation.[2] Serious side effects may include suicide, abuse.[2] Use is not recommended during pregnancy.[1] Phentermine is a stimulant and appetite suppressant.[2] Topiramate is an anticonvulsant that has weight loss side effects.[2] The exact mechanism of action for both drugs is unknown.[2]
Phentermine/topiramate was approved for medical use in the United States in 2012.[2] In October 2012, approval was denied in Europe, due to concerns regarding safety.[3][4][5]
- ^ a b "Phentermine and topiramate Uses, Side Effects & Warnings". Drugs.com. Retrieved 13 April 2019.
- ^ a b c d e f g h i j "DailyMed - Qsymia - phentermine and topiramate capsule, extended release". dailymed.nlm.nih.gov. Retrieved 13 April 2019.
- ^ "www.ema.europa.eu" (PDF). Archived from the original (PDF) on 21 December 2014.
- ^ Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, et al. (January 2021). "Long-term effects of weight-reducing drugs in people with hypertension". The Cochrane Database of Systematic Reviews. 1 (1): CD007654. doi:10.1002/14651858.CD007654.pub5. PMC 8094237. PMID 33454957.
- ^ "Qsiva". EMA. 13 June 2013.